Margaret A Shipp

USPTO Granted Patents = 15 (Patent Applications = 7)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

15 out of 1,206

Dana-farber-cancer Institute Inc.

The Brigham and Women's Hospital, Inc.

patents

4. 3 out of 74

Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet)

Consejo Nactional De Investigaciones Cientificias Y Tecnicas

patent

7. 1 out of 443

The Broad Institute, Inc.

patents

where one patent can have more than one assignee

Years Active: 2005-2023

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11723972 - Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 (2023-08-15),

2. 11673956 - Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1 (2023-06-13),

3. 11446309 - Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors (2022-09-20),

4. 10844126 - Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing GAL1 (2020-11-24),

5. 10519238 - Anti-galectin-1 monoclonal antibodies and fragments thereof (2019-12-31),

6. 10456465 - Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 (2019-10-29),

7. 9939428 - Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1 (2018-04-10),

8. 9890429 - Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer (2018-02-13),

9. 9840708 - Compositions and methods for the modulation of DNA damage responses using BAL1 and BBAP (2017-12-12),

10. 9206427 - Compositions, kits, and methods for the modulation of immune responses using galectin-1 (2015-12-08),

11. 8968740 - Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 (2015-03-03),

12. 7858742 - Lymphoma associated molecules and uses therefor (2010-12-28),

13. 7632660 - Lymphoma associated molecules and uses therefor (2009-12-15),

14. 7112420 - Lymphoma associated molecules and uses therefor (2006-09-26),

15. 6870040 - Nucleic acid sequence encoding lymphoma associated molecule BAL (2005-03-22),

Title: Innovations and Contributions of Inventor Margaret A. Shipp

Introduction

Margaret A. Shipp is a prominent inventor based in Wellesley, MA, known for her significant contributions to the field of medical research. With a total of 15 patents to her name, she has made remarkable strides in the diagnosis and treatment of various disorders.

Latest Patents

Her latest patents include groundbreaking work on compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment, and modulation of post-transplant lymphoproliferative disorders and hypoxia-associated angiogenesis disorders using galectin-1. This invention is based on the discovery that galectin-1 (Gal1) plays a crucial role in viral-associated PTLD, such as EBV-associated PTLD and hypoxia-associated angiogenesis disorders. Additionally, she has developed anti-galectin-1 (Gal1) monoclonal antibodies and fragments for neutralizing Gal1, which are essential for neutralizing Gal1 function.

Career Highlights

Throughout her career, Margaret has worked with esteemed organizations, including the Dana-Farber Cancer Institute Inc. and Fundacion Sales. Her work has significantly impacted the understanding and treatment of complex medical conditions.

Collaborations

Margaret has collaborated with notable colleagues, including Scott J. Rodig and Jing Ouyang, further enhancing her research and contributions to the field.

Conclusion

Margaret A. Shipp's innovative work and dedication to medical research have led to significant advancements in the diagnosis and treatment of critical health issues. Her contributions continue to influence the medical community and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.